ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Endoscopic Sleeve Gastroplasty for Type 2 Diabetes: A Systematic Review and Meta-Analysis Focusing on Diabetes Remission, Glycemic Control and Body Weight Loss.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate metabolic outcomes of endoscopic sleeve gastroplasty (ESG) in patients with type 2 diabetes mellitus (T2DM), focusing on T2DM remission, T2DM improvement, glycated hemoglobin (HbA1c), and percentage of total body weight loss (%TBWL). Methods: PubMed, Embase, Web of Science, Cochrane Library, and MEDLINE were searched for cohort studies through December 2025. Two investigators independently performed screening, data extraction, and quality assessment using the Newcastle-Ottawa Scale. Primary outcomes were T2DM remission, T2DM improvement, HbA1c change, and %TBWL. Meta-analyses used random- or fixed-effects models. Subgroup and sensitivity analyses and Egger's test assessed stability and publication bias. Results: Seven observational cohort studies involving 519 patients with T2DM were included. The pooled Freeman-Tukey transformed effect size for T2DM remission after ESG was 1.89 (95% confidence interval [CI]: 1.71, 2.06, P < 0.001), corresponding to a raw pooled diabetes remission rate of 62.3%; the pooled transformed effect size for T2DM improvement was 1.65 (95% CI [1.04, 2.26], P < 0.001), with an overall raw improvement rate of 59.1%. The pooled mean difference for HbA1c was 0.60% (95% CI [0.23, 0.97], P = 0.001), and for %TBWL was 10.89% (95% CI [6.24, 15.54], P < 0.001). Subgroup analyses showed %TBWL of 12.84% (95% CI [10.86, 14.82]) at 12 months and 14.00% (95% CI [11.76, 16.24]) at 3 years. Patients with baseline HbA1c ≥ 7.0% had greater HbA1c reduction than those with baseline HbA1c < 7.0% (-1.00% vs -0.50%). Conclusion: ESG improves T2DM remission, glycemic control, and weight loss, with effects sustained up to 3 years. Patients with higher baseline glycemic levels derived greater benefits. ESG may represent an effective minimally invasive treatment option for T2DM, although further randomized trials are needed to confirm this finding.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.